FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
1/22/2025 9:54:42 PM | Chg. -0.330 | Volume | Bid9:58:34 PM | Ask9:58:34 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
35.870EUR | -0.91% | 37,491 Turnover: 1.35 mill. |
35.630Bid Size: 550 | 35.870Ask Size: 500 | 20.14 bill.EUR | - | - |
GlobeNewswire
4/24/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
4/23/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil